title: Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
abstract: The synthesis of some new aminoadamantane derivatives is described. The new compounds were evaluated against a wide range of viruses [influenza A H1N1, influenza A H2N2, influenza A H3N2, influenza B, parainfluenza 3, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), thymidine kinase-deficient (TK-) HSV-1, vaccinia, vesicular stomatitis, polio 1, Coxsackie B4, Sindbis, Semliki forest, Reo 1, varicella-zoster virus (VZV), TK- VZV, human cytomegalovirus (HCMV), and human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)]. Some of them proved markedly active against the influenza A H2N2 (compounds 4a,b, 5a, 6a, and 7a), H3N2 (compounds 5a, 6a, and 7a), and H1N1 (compounds 4b,c and 6d). Since compounds 5a, 6a, and 7a, amantadine, and rimantadine showed the same comparative pattern of potency against influenza strains H2N2, H3N2, and B, it may postulated that they act according to a similar mechanism, with regard to their "amine" effect, on the M2 ion channel of influenza A (H1N1, H2N2, or H3N2). In general, no significant activity was noted with any of the new compounds against any of the other viruses tested, making their activity against influenza virus more specific and striking. Borderline activity was noted with some of the compounds (4b,c, 5a-c, and 8a) against HIV-1.
authors.affiliation: Department of Pharmacy, University of Athens, Panepistimioupoli-Zografou, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Kolocouris
authors.forename: A
authors.initials: A
authors.lastname: Kolocouris
authors.forename: G B
authors.initials: GB
authors.lastname: Foscolos
authors.forename: G
authors.initials: G
authors.lastname: Fytas
authors.forename: J
authors.initials: J
authors.lastname: Neyts
authors.forename: E
authors.initials: E
authors.lastname: Padalko
authors.forename: J
authors.initials: J
authors.lastname: Balzarini
authors.forename: R
authors.initials: R
authors.lastname: Snoeck
authors.forename: G
authors.initials: G
authors.lastname: Andrei
authors.forename: E
authors.initials: E
authors.lastname: De Clercq
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D002460:Cell Line; D002522:Chlorocebus aethiops; D003587:Cytomegalovirus / Q000187:drug effects; D004285:Dogs; D029822:Enterovirus B, Human / Q000187:drug effects; D015497:HIV-1 / Q000187:drug effects; D015498:HIV-2 / Q000187:drug effects; D014645:Herpesvirus 3, Human / Q000187:drug effects; D006801:Humans; D007202:Indicators and Reagents; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D009975:Orthomyxoviridae / Q000187:drug effects; D012087:Reoviridae / Q000187:drug effects; D012672:Semliki forest virus / Q000187:drug effects; D012845:Sindbis Virus / Q000187:drug effects; D013329:Structure-Activity Relationship; D014616:Vaccinia virus / Q000187:drug effects; D014721:Vesicular stomatitis Indiana virus / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D007202:Indicators and Reagents; D000218:Adamantane